COSTEM 2023 | Indirect comparison of brexu-cel versus SOC in R/R MCL
Georg Hess, MD, University Medical Center Mainz, Mainz, Germany, discusses the findings from an indirect comparison of brexucabtagene autoleucel (brexu-cel) versus standard of care (SOC) in relapsed/refractory (R/R) mantle cell lymphoma (MCL). This interview took place at The 8th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM 2023), held in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Abbvie, ADC-Therapeutics, AstraZenaeca, BMS, Genmab, Gilead/Kite, Incyte, Janssen, Lilly, Miltenyi, Novartis, Roche
Honoraria: Abbvie, AstraZeneca, Beigene, BMS, Genmab, Gilead/Kite, Incyte, Janssen, Lilly, Roche
Research Funding: Abbvie, Gilead/Kite, Incyte, Janssen, Morphosys, Roche
Patents and Royalties: not applicable
Membership on an entity’s Board of Directors or advisory committees: not applicable
Discussion of off-label drug use: not applicable
Travel grants: Gilead/Kite, Janssen
